# BioGaia > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/biogaiab). ## Overview BioGaia AB is a Swedish company specializing in the development, manufacturing, and marketing of probiotic products aimed at enhancing gut, oral, and immune health. With over 35 years of experience in microbiome research, BioGaia is a leader in the probiotic industry, primarily utilizing strains of the lactic acid bacterium Limosilactobacillus reuteri. The company's products are distributed globally through partnerships and direct sales, and its shares are listed on the Nasdaq Stockholm Mid Cap List. ## Products & services • BioGaia Protectis BABY drops with Vitamin D • BioGaia Prodentis lozenges for oral health • BioGaia Gastrus chewable tablets for gut health • BioGaia Pharax kids drops • Bacterial cultures for licensee products - **Gut Health Products** (40%) — Includes colic drops and chewable tablets for gut health. - **Oral Health Products** (25%) — Includes lozenges and tablets for oral health. - **Immune Health Products** (15%) — Products designed to support immune health. - **Licensee Products** (20%) — Bacterial cultures sold for use in other companies' products. - BioGaia Protectis BABY drops with Vitamin D - BioGaia Prodentis lozenges for oral health - BioGaia Gastrus chewable tablets for gut health - BioGaia Pharax kids drops - Bacterial cultures for licensee products ## Customers BioGaia's customer base is diverse, spanning across nutrition and pharmaceutical companies, healthcare providers, and direct consumers. The company partners with major nutrition and pharmaceutical firms to distribute its products in over 100 countries. Consumers seeking probiotic supplements for gut, oral, and immune health form a significant part of its customer base. BioGaia also caters to licensees who incorporate its bacterial cultures into their own products, such as infant formula and dairy products. - **Nutrition Companies** (primary) — Purchase bacterial cultures for integration into their products. - **Pharmaceutical Companies** (primary) — Distribute BioGaia's probiotic products globally. - **Direct Consumers** (secondary) — Buy probiotic supplements for personal health benefits. - **Licensees** (secondary) — Incorporate BioGaia's strains into their own products. - Nutrition companies buy bacterial cultures for product integration. - Pharmaceutical companies distribute BioGaia's probiotic products. - Healthcare providers recommend BioGaia products for gut and oral health. - Consumers purchase BioGaia supplements for personal health benefits. - Licensees use BioGaia's strains in infant formula and dairy products. ## Geography BioGaia operates in over 100 countries, with direct sales subsidiaries in nine key markets including Sweden, Finland, France, the UK, USA, Canada, Australia, New Zealand, and Japan. The company's strategic geographic presence allows it to cater to diverse markets and leverage local partnerships. BioGaia's products are particularly popular in North America and the APAC region, where demand for probiotics is strong. The company also holds patents in all major markets, protecting its proprietary strains and packaging solutions. - Operates in over 100 countries with a strong presence in North America and APAC. - Direct sales subsidiaries in nine countries including Sweden and the USA. - Holds patents in all major markets for proprietary strains and packaging. - Strong demand in North America, particularly in the USA and Canada. - APAC region shows robust growth driven by online sales and marketing. ## Strategy BioGaia's strategic priorities focus on expanding its brand presence and increasing direct sales. The company aims to strengthen its position in the adult health segment, which has shown significant growth. BioGaia is also enhancing its online sales channels to reach a broader audience. The company is committed to maintaining a strong operating margin while investing in marketing and distribution to support growth in key markets. - **Expand direct sales** (medium-term) — To increase market penetration and control distribution. - **Focus on adult health segment** (short-term) — To capitalize on growing demand for adult probiotics. - **Enhance online sales** (medium-term) — To reach a wider consumer base and increase sales. - Expand brand presence and increase direct sales in key markets. - Focus on the growing adult health segment with products like BioGaia Gastrus. - Enhance online sales channels to reach a broader audience. - Maintain strong operating margins while investing in marketing. - Leverage patents to protect proprietary strains and packaging solutions. ## Risks BioGaia faces several risks, including market competition, regulatory changes, and currency fluctuations. The company's reliance on distribution partners poses a risk if partnerships are terminated or underperform. Regulatory changes in health and safety standards could impact product approvals and market access. Currency fluctuations, particularly with the Swedish Krona, can affect financial results. Additionally, the company's growth strategy depends on successful market penetration in new regions, which may present operational challenges. - **Market competition** [high] — High competition in the probiotic industry could affect market share. - **Regulatory changes** [medium] — Changes in health standards could impact product approvals. - **Currency fluctuations** [high] — Fluctuations in SEK can affect profitability. - Market competition from other probiotic brands. - Regulatory changes affecting product approvals. - Currency fluctuations impacting financial results. - Reliance on distribution partners for global reach. - Operational challenges in penetrating new markets. ## Accounting BioGaia's financial statements are influenced by several critical accounting matters, including revenue recognition and currency translation adjustments. The company recognizes revenue from product sales and royalties, which can be affected by timing and contractual terms. Currency translation adjustments are significant due to BioGaia's global operations and the impact of exchange rate fluctuations on financial results. Fair value measurements for financial liabilities related to acquisitions are also crucial, as they involve significant judgment and estimation. - **Revenue recognition** - **Currency translation adjustments** - **Fair value measurements** - Revenue recognition timing affects reported sales and royalties. - Currency translation adjustments impact financial results. - Fair value measurements for financial liabilities require judgment. - Estimates and provisions for acquisitions affect financial statements. - Accounting for stock options impacts employee compensation costs. --- *Last updated: 2026-08-11T04:04:51.235398+00:00*